Obstructive sleep apnea (OSA) occurs when throat muscles relax during sleep and block the airway, causing repeated breathing interruptions that disrupt sleep and stress the heart and brain. CPAP is highly effective but difficult to tolerate long-term, which is why alternatives are urgently needed.
What's actually going on in research
A combination of two drugs — atomoxetine plus oxybutynin — activates upper airway muscles during sleep and has shown significant reductions in apnea events, representing the first promising drug treatment for OSA. Hypoglossal nerve stimulators that electrically activate tongue muscles during sleep are being refined and expanded to more patients. GLP-1 agonists used for weight loss are showing substantial OSA improvement, and large trials are now documenting cardiovascular benefits specifically in OSA patients.
Drug therapy (AD110)
The combination of atomoxetine and oxybutynin targets the upper airway muscle tone lost during sleep in OSA. Trials are refining dosing and testing this approach in diverse patient populations.
Hypoglossal stimulation
Surgically implanted devices that stimulate the hypoglossal nerve during sleep to keep the tongue and airway open are being tested in broader populations including children and positional OSA.
GLP-1 weight loss effects
Semaglutide and other GLP-1 agonists reduce weight substantially and have shown dramatic OSA improvement. Trials are documenting cardiovascular and cognitive benefits of OSA treatment through this pathway.
What to know before you search
Eligibility depends on AHI severity, BMI, anatomy score, CPAP failure or intolerance, and presence of cardiovascular comorbidities.
What types of trials are currently open
- Drug trials — Testing medications that improve upper airway muscle tone or ventilatory control during sleep.
- Device trials — Evaluating hypoglossal nerve stimulators, mandibular advancement devices, and positional therapy devices.
- CPAP improvement trials — Testing interfaces, auto-titration algorithms, and adherence interventions to improve CPAP use.
- Weight loss trials — Evaluating GLP-1 agonists and other weight-reduction strategies as OSA treatment.
- Cardiovascular outcomes trials — Testing whether OSA treatment reduces blood pressure, heart disease risk, and stroke in high-risk patients.
Recently added Obstructive Sleep Apnea trials
Assessment of Heart Rate Variability for Predicting Obstructive Sleep Apnea in Patients With Hypertension
This study aims to investigate the relationship between hypertension and obstructive sleep apnea (OSA) using heart rate variability (HRV) as a non-invasive biomarker of autonomic nervous system function. Hypertensive patients at high risk for OSA will undergo 24-hour Holter electrocardiogram monitoring to assess HRV parameters, along with overnight polysomnography (PSG) to determine OSA severity. The study will analyze the association between HRV indices and the apnea-hypopnea index (AHI), and develop predictive models using machine learning techniques. In addition, patients diagnosed with OSA will be followed after treatment, and changes in HRV and blood pressure will be evaluated to assess treatment effects and autonomic function recovery. The results of this study may provide a cost-effective and clinically applicable approach for early detection, risk stratification, and management of OSA in patients with hypertension.
The Impact of Volume Overload on Obstructive Sleep Apnea in Patients With Congestive Heart Failure
The goal of this observational study is to learn how removing extra fluid from the body (diuresis) affects sleep apnea in adults hospitalized with heart failure. The main questions it aims to answer are: Does sleep apnea severity improve after fluid removal? Is the improvement in sleep apnea related to the amount of fluid removed? Do changes in neck size reflect changes in sleep apnea severity? Participants admitted to the hospital with heart failure and fluid overload will take part in this study. Participants will: Use a wearable sleep monitoring device (WatchPAT) on the first night of hospitalization Use the device again after fluid removal, when the treating cardiologist determines that the patient is no longer fluid overloaded Have their neck circumference measured before and after fluid removal Have their weight and fluid balance recorded during hospitalization Have routine blood tests and clinical assessments as part of standard care Researchers will compare each participant's results before and after fluid removal to see if sleep apnea improves and whether these changes are linked to fluid removal and changes in neck circumference.
Find Obstructive Sleep Apnea trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.